|
Dan Nieuwlandt has been involved in the field of in vitro evolution (SELEX and Evolutionary Chemistry) for over 12 years. Dr. Nieuwlandt is currently a Senior Scientist with SomaLogic, Inc., a Boulder, Colorado company that utilizes in vitro evolution and its unique aptamer array and bioinformatics capabilities to discover disease-specific biomarkers and protein signatures. Prior to his SomaLogic appointment, he served as Vice President, Biology, at Invenux, Inc. (2000-3), where he directed all biology efforts, including drug target evaluation and the development of new in vitro evolution methodologies for the company’s Evolutionary Chemistry (EC) technology. During his tenure at Invenux, Dr. Nieuwlandt was largely responsible for transferring the EC technology (biochemistry components) to Cropsolution, Inc. Prior to his Invenux position, he was employed by Nexstar Pharmaceuticals, Inc. (1994-9), where he succeeded in RNA aptamer in vitro evolution efforts directed at numerous disease-diagnostic targets, and was an Associate Director in the Evolutionary Chemistry group where he was an integral member of the team that developed the EC technology. Dr. Nieuwlandt completed a postdoctoral fellowship, with a focus on in vitro evolution methodologies (when the field was in its infancy), in the laboratory of Dr. Larry Gold at the University of Colorado (1992-4). He received his Ph.D. and M.S. degrees in microbiology from The Ohio State University (catalytic RNA research) and Iowa State University (Staphylococcus aureus genetics), respectively, and his B.A. in biology from California State University, Fullerton. | 